- This event has passed.
Impact of pharmaceutical innovation on premature mortality and hospitalisation in Australia
October 18 @ 9:30 am - 11:00 am
KPMG and Medicines Australia, supported by Bristol-Myers Squibb, Roche, Sanofi, MSD and GSK, are pleased to be holding an exclusive presentation and panel discussion and we encourage you to join the conversation.
This event will feature a keynote address from Professor Frank Lichtenberg – the Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business. Professor Lichtenberg will present his findings on the impact of pharmaceutical innovation on premature mortality and hospitalisation in Australia, 1998-2018. This will be followed by a panel discussion with audience participation.
Professor Lichtenberg’s compelling analysis highlights that pharmaceutical innovation is responsible for almost all of the decline in premature mortality between 1998 and 2015 and outcomes from his research continues the discussion about the environment for new medicines in Australia.
Friday, 18th October, 2019
9.30am to 11am – Presentation followed by panel discussion (a light breakfast buffet and tea plus coffee will be provided)
International Towers Sydney 3
300 Barangaroo Avenue
SYDNEY NSW 2000
RSVP and contact details
Please RSVP to Danny Brayan by Thursday, 10th October or if you have any questions:
Email: email@example.com Phone: 0409 582 369
About Professor Lichtenberg
Professor Frank Lichtenberg, Courtney C. Brown Professor of Business Economics & Courtney C. Brown Professor of Business Healthcare and Pharmaceutical Management Program
Frank R. Lichtenberg is Courtney C. Brown Professor of Business at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.
Mr. Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Dept. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.
Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organizations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.
He was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research! America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.
He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organizations. He has served as a consultant to private organizations and government agencies including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council. He is an affiliate of the economics consulting firm Analysis Group.